- March 12, 2013
WEST ST. PAUL, MN | Tapemark announces the addition of several new capabilities for transdermal patches, including the formulation, blending, and coating steps in the patch manufacturing process. Combined with existing converting and packaging expertise, company now is a fully integrated transdermal contract development and manufacturing organization (CDMO), from active pharmaceutical ingredient (API) to the finished transdermal patch.
Andy Rensink, Tapemark president and COO, explains that upon its 60th anniversary, the company recently invested heavily in expanding both its capabilities and its physical facilities in the realm of transdermals. He says the company also is adding staff to support the new capabilities. “…We anticipate strong growth for Tapemark and for the pharma industry, especially as generic drugs continue their push for market share in transdermal patches.”